These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 21939646)

  • 1. Seasonal variation and stability of matrix metalloproteinase-9 activity and tissue inhibitor of matrix metalloproteinase-1 with storage at -80°C.
    Tarr GP; Williams MJ; Phillips LV; van Rij AM; Jones GT
    Clin Biochem; 2011 Nov; 44(16):1346-8. PubMed ID: 21939646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pro-MMP-9/TIMP-1 ratio correlates poorly with a direct assessment of MMP-9 activity.
    Tarr GP; Williams MJ; Phillips LV; van Rij AM; Jones GT
    Clin Biochem; 2011 Dec; 44(17-18):1480-2. PubMed ID: 22020222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma storage at -80 degrees C does not protect matrix metalloproteinase-9 from degradation.
    Rouy D; Ernens I; Jeanty C; Wagner DR
    Anal Biochem; 2005 Mar; 338(2):294-8. PubMed ID: 15745750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relation of matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio in peripheral circulating CD14+ monocytes to progression of coronary artery disease.
    Brunner S; Kim JO; Methe H
    Am J Cardiol; 2010 Feb; 105(4):429-34. PubMed ID: 20152234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome.
    Inokubo Y; Hanada H; Ishizaka H; Fukushi T; Kamada T; Okumura K
    Am Heart J; 2001 Feb; 141(2):211-7. PubMed ID: 11174334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of low-density lipoprotein apheresis on plasma matrix metalloproteinase-9 and serum tissue inhibitor of metalloproteinase-1 levels in diabetic hemodialysis patients with arteriosclerosis obliterans.
    Nakamura T; Matsuda T; Suzuki Y; Ueda Y; Koide H
    ASAIO J; 2003; 49(4):430-4. PubMed ID: 12918586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
    Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
    Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension.
    Derosa G; D'Angelo A; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo S; Montagna L; Gravina A; Ferrari I; Galli S; Paniga S; Tinelli C; Cicero AF
    Endothelium; 2006; 13(3):227-31. PubMed ID: 16840178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).
    Tayebjee MH; Nadar S; Blann AD; Gareth Beevers D; MacFadyen RJ; Lip GY
    Am J Hypertens; 2004 Sep; 17(9):764-9. PubMed ID: 15363817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 during human orthotopic liver transplantation. The effect of aprotinin and the relation to ischemia/reperfusion injury.
    Kuyvenhoven JP; Molenaar IQ; Verspaget HW; Veldman MG; Palareti G; Legnani C; Moolenburgh SE; Terpstra OT; Lamers CB; van Hoek B; Porte RJ
    Thromb Haemost; 2004 Mar; 91(3):506-13. PubMed ID: 14983226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer.
    Oberg A; Höyhtyä M; Tavelin B; Stenling R; Lindmark G
    Anticancer Res; 2000; 20(2B):1085-91. PubMed ID: 10810401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers.
    Keyszer G; Lambiri I; Nagel R; Keysser C; Keysser M; Gromnica-Ihle E; Franz J; Burmester GR; Jung K
    J Rheumatol; 1999 Feb; 26(2):251-8. PubMed ID: 9972954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta.
    Boz C; Ozmenoglu M; Velioglu S; Kilinc K; Orem A; Alioglu Z; Altunayoglu V
    Clin Neurol Neurosurg; 2006 Feb; 108(2):124-8. PubMed ID: 16412833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Plasma matrix metalloproteinases MMP-2 and MMP-9 and tissue inhibitors TIMP-1 and TIMP-2 in children treated for acute lymphoblastic leukemia].
    Krawczuk-Rybak M; Kuźmicz M; Mroczko B; Szmitkowski M
    Pol Merkur Lekarski; 2010 Jul; 29(169):14-8. PubMed ID: 20712241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of matrix metalloproteinase (MMP)-2, MMP-8, MMP-9, and their inhibitors, the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in obese children and adolescents.
    Belo VA; Souza-Costa DC; Lana CM; Caputo FL; Marcaccini AM; Gerlach RF; Bastos MG; Tanus-Santos JE
    Clin Biochem; 2009 Jul; 42(10-11):984-90. PubMed ID: 19358835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) and their tissue inhibitors (TIMP-1 and TIMP-2) in differential diagnosis between low malignant potential (LMP) and malignant ovarian tumours.
    Määtta M; Talvensaari-Mattila A; Turpeenniemi-Hujanen T; Santala M
    Anticancer Res; 2007; 27(4C):2753-8. PubMed ID: 17695443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of the metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system on large arterial stiffness in patients with essential hypertension.
    Tan J; Hua Q; Xing X; Wen J; Liu R; Yang Z
    Hypertens Res; 2007 Oct; 30(10):959-63. PubMed ID: 18049028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Matrix metalloproteinase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis.
    Benesová Y; Vasku A; Novotná H; Litzman J; Stourac P; Beránek M; Kadanka Z; Bednarík J
    Mult Scler; 2009 Mar; 15(3):316-22. PubMed ID: 19153173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum concentrations of matrix metalloproteinase-9, tissue inhibitor of matrix metalloproteinase-1 and alpha2-macroglobulin in healthy subjects after supplementation with different doses of marine n-3 fatty acids.
    Vogt J; Andersen VL; Andreasen A; Obel T; Christensen JH; Schmidt EB
    Cell Mol Biol (Noisy-le-grand); 2010 Feb; 56(1):102-9. PubMed ID: 20196974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Matrix metalloproteinases in premature coronary atherosclerosis: influence of inhibitors, inflammation, and genetic polymorphisms.
    Nanni S; Melandri G; Hanemaaijer R; Cervi V; Tomasi L; Altimari A; Van Lent N; Tricoci P; Bacchi L; Branzi A
    Transl Res; 2007 Mar; 149(3):137-44. PubMed ID: 17320799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.